Good summary indeed.  I have question for Bear or one of the physiologists or docs on board.

Is there an obvious physiological linkage between two of the most surprising negative outcomes of the trial:  apabetalone failed to reduce strokes in the overall study population and failed to reduce MACE events in the high LDL (above median) subgroup?  Specifically, is there a known causal or correlational relationship between high LDL and strokes that is not also true for high LDL and heart attacks or CV death (or congestive heart failure)?

Thanks,

Jupe